Company Analysis

BioXcel Therapeutics, Inc. (BTAI)

OTC: BTAI · Pharmaceutical Preparations · New Haven, CT · filing with the SEC since 2017
Grade3.3
◀ Past 2.9● Present 3.1▶ Future 3.7
1 est.

Who runs BioXcel Therapeutics, Inc.

Officers and directors as they report to the SEC on Forms 3, 4 and 5, named as filed
Chief executive, as filed
Mehta Vimal
CEO and President. First filing Mar 2018, latest Jun 17, 2026, 18 filings in all.
Officers reporting now
4
of 12 people with a filing in the last fifteen months
Directors reporting now
8
17 people on the record since 2018
Officerssales are open-market, Sep 30, 2025 to Sep 30, 2026
NameTitle as filedFirst filingLatest filingSales, 12 months
Mehta VimalCEO and PresidentMar 2018Jun 17, 20261 · $0.00
Rodriguez JavierChief Legal Officer, Senior Vice President and Corporate SecretaryFeb 2021Jun 17, 20261 · $0.00
Steinhart Richard IChief Financial OfficerMar 2018Jun 17, 20261 · $0.00
Yocca FrankChief Scientific OfficerMar 2018Jun 17, 20261 · $0.00
Directorssales are open-market, Sep 30, 2025 to Sep 30, 2026
NameRoleFirst filingLatest filingSales, 12 months
Atkins Susan E.directorAug 2026Aug 14, 2026none
Bray JunedirectorMar 2021Jan 12, 2026none
Laumas SandeepdirectorMar 2018Jan 12, 2026none
Mack David J.directorNov 2024Jan 12, 2026none
Miller Michael PatrickdirectorJul 2022Jan 12, 2026none
Mueller PeterdirectorMar 2018Jan 12, 2026none
Patni RajivdirectorJan 2025Jan 12, 2026none
Votruba MichaldirectorMar 2019Jan 12, 2026none
Earlier names on the record23, newest filing first

A person is listed as reporting now after a filing in the last fifteen months. The record shows when someone last filed; it does not say why they stopped. Each name links to the filings on sec.gov.

SI Assistanton BTAI · research, not advice